Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016

Market: Pharmaceuticals and Healthcare

Global, 177 pages report, published by GlobalData

Keywords : Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO’s, Terminated, Suspended and Withdrawn trials of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania.

Report ThumbnailDecember-2016
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016" provides an overview of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
  • List of Figures
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 17
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31
  • GlobalData Methodology 175
  • List of Tables
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, G7 Countries (%), 2016* 14
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials, E7 Countries (%), 2016* 18
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Phase, 2016* 21
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 28
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 30
  • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 31
  • Table of Contents
  • Table of Contents 2
  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Five Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections to Infectious Disease Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Clinical Trials 29
  • Prominent Drugs 31
  • Latest Clinical Trials News on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 32
  • Dec 08, 2016: Citius Moves Forward with Mino-Lok Phase 3 Trial 32
  • Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4 32
  • Nov 08, 2016: HKU Chemists achieve breakthrough in antibacterial drug research 33
  • Oct 26, 2016: Tetraphase Pharmaceuticals Announces Eight Data Presentations at IDWeek 2016 33
  • Oct 20, 2016: MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA 34
  • Oct 18, 2016: Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV (telavancin), Including Ongoing TOUR Observational Patient Registry, at IDWeek 2016 35
  • Oct 04, 2016: Online Media Group covers Phase 3 clinical Trial 35
  • Clinical Trial Profile Snapshots 37
  • Appendix 174
  • Abbreviations 174
  • Definitions 174
  • Research Methodology 175
  • Secondary Research 175
  • About GlobalData 176
  • Contact Us 176
  • Disclaimer 176
  • Source 177

Please select a license type

Share

Related Products

GlobalDataMethicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016Product ThumbnailMethicillin-Resistant Staphylococcus aureus (MRSA) Infections Global Clinical Trials Review, H2, 2016, Industry Report available for $2500Product #: 631444
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved